

# World Journal of *Clinical Cases*

*World J Clin Cases* 2022 February 16; 10(5): 1457-1753



## Contents

Thrice Monthly Volume 10 Number 5 February 16, 2022

## REVIEW

- 1457 Nonalcoholic fatty liver disease shows significant sex dimorphism  
*Chen XY, Wang C, Huang YZ, Zhang LL*

## MINIREVIEWS

- 1473 Management of procedural pain in the intensive care unit  
*Guo NN, Wang HL, Zhao MY, Li JG, Liu HT, Zhang TX, Zhang XY, Chu YJ, Yu KJ, Wang CS*

## ORIGINAL ARTICLE

## Clinical and Translational Research

- 1485 Effect of prior malignancy on the prognosis of gastric cancer and somatic mutation  
*Yin X, He XK, Wu LY, Yan SX*

## Retrospective Cohort Study

- 1498 Elemene-containing hyperthermic intraperitoneal chemotherapy combined with chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer  
*Chen ZX, Li J, Liu WB, Zhang SR, Sun H*

## Retrospective Study

- 1508 Timing theory continuous nursing, resistance training: Rehabilitation and mental health of caregivers and stroke patients with traumatic fractures  
*Shen YL, Zhang ZQ, Zhu LJ, Liu JH*
- 1517 Effect of precise nursing service mode on postoperative urinary incontinence prevention in patients with prostate disease  
*Zheng XC, Luo TT, Cao DD, Cai WZ*

- 1527 Significance of serum glucagon-like peptide-1 and matrix Gla protein levels in patients with diabetes and osteoporosis  
*Xie FF, Zhang YF, Hu YF, Xie YY, Wang XY, Wang SZ, Xie BQ*

- 1536 Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key  
*Zhou QY*

## Observational Study

- 1548 Correlation of myopia onset and progression with corneal biomechanical parameters in children  
*Lu LL, Hu XJ, Yang Y, Xu S, Yang SY, Zhang CY, Zhao QY*

**META-ANALYSIS**

- 1557** Intensive *vs* non-intensive statin pretreatment before percutaneous coronary intervention in Chinese patients: A meta-analysis of randomized controlled trials

*Yang X, Lan X, Zhang XL, Han ZL, Yan SM, Wang WX, Xu B, Ge WH*

**CASE REPORT**

- 1572** Giant nodular fasciitis originating from the humeral periosteum: A case report  
*Yu SL, Sun PL, Li J, Jia M, Gao HW*
- 1580** Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report  
*Deng PB, Jiang J, Hu CP, Cao LM, Li M*
- 1586** Submucosal protuberance caused by a fish bone in the absence of preoperative positive signs: A case report  
*Du WW, Huang T, Yang GD, Zhang J, Chen J, Wang YB*
- 1592** Misdiagnosis of unroofed coronary sinus syndrome as an ostium primum atrial septal defect by echocardiography: A case report  
*Chen JL, Yu CG, Wang DJ, Chen HB*
- 1598** Uncommon complication of nasoenteral feeding tube: A case report  
*Jiang YP, Zhang S, Lin RH*
- 1602** Treatment of extracranial internal carotid artery dissecting aneurysm with SUPERA stent implantation: Two case reports  
*Qiu MJ, Zhang BR, Song SJ*
- 1609** Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report  
*Wang J, Gao YS, Xu K, Li XD*
- 1617** Hemangioma in the lower labial vestibule of an eleven-year-old girl: A case report  
*Aloyouny AY, Alfaifi AJ, Aladhyani SM, Alshalan AA, Alfayadh HM, Salem HM*
- 1623** Primary orbital monophasic synovial sarcoma with calcification: A case report  
*Ren MY, Li J, Li RM, Wu YX, Han RJ, Zhang C*
- 1630** Small-cell carcinoma of the prostate with negative CD56, NSE, Syn, and CgA indicators: A case report  
*Shi HJ, Fan ZN, Zhang JS, Xiong BB, Wang HF, Wang JS*
- 1639** Disseminated peritoneal leiomyomatosis with malignant transformation involving right ureter: A case report  
*Wen CY, Lee HS, Lin JT, Yu CC*

- 1645** Arthroscopic surgery for synovial chondroma of the subacromial bursa with non-traumatic shoulder subluxation complications: Two case reports  
*Tang XF, Qin YG, Shen XY, Chen B, Li YZ*
- 1654** Wilkie's syndrome as a cause of anxiety-depressive disorder: A case report and review of literature  
*Apostu RC, Chira L, Colcear D, Lebovici A, Nagy G, Scurtu RR, Drasovean R*
- 1667** Gastric schwannoma misdiagnosed as gastrointestinal stromal tumor by ultrasonography before surgery: A case report  
*Li QQ, Liu D*
- 1675** Giant retroperitoneal lipoma presenting with abdominal distention: A case report and review of the literature  
*Chen ZY, Chen XL, Yu Q, Fan QB*
- 1684** Pneumothorax during retroperitoneal laparoscopic partial nephrectomy in a lupus nephritis patient: A case report  
*Zhao Y, Xue XQ, Xia D, Xu WF, Liu GH, Xie Y, Ji ZG*
- 1689** Bulbar conjunctival vascular lesion combined with spontaneous retrobulbar hematoma: A case report  
*Lei JY, Wang H*
- 1697** Hepatitis B virus in cerebrospinal fluid of a patient with purulent bacterial meningitis detected by multiplex-PCR: A case report  
*Gao DQ, Hu YQ, Wang X, Zhang YZ*
- 1702** Aseptic abscess in the abdominal wall accompanied by monoclonal gammopathy simulating the local recurrence of rectal cancer: A case report  
*Yu Y, Feng YD, Zhang C, Li R, Tian DA, Huang HJ*
- 1709** Tacrolimus treatment for relapsing-remitting chronic inflammatory demyelinating polyradiculoneuropathy: Two case reports  
*Zhu WJ, Da YW, Chen H, Xu M, Lu Y, Di L, Duo JY*
- 1716** Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report  
*Zhang J, Liu MH, Gao X, Dong C, Li YX*
- 1723** Unusual magnetic resonance imaging findings of brain and leptomeningeal metastasis in lung adenocarcinoma: A case report  
*Li N, Wang YJ, Zhu FM, Deng ST*
- 1729** Diffuse invasive signet ring cell carcinoma in total colorectum caused by ulcerative colitis: A case report and review of literature  
*Zhang Z, Yu PF, Gu GL, Zhang YH, Wang YM, Dong ZW, Yang HR*
- 1738** Neurothekeoma located in the hallux and axilla: Two case reports  
*Huang WY, Zhang YQ, Yang XH*



- 1747** Subclavian artery stenting *via* bilateral radial artery access: Four case reports

*Qiu T, Fu SQ, Deng XY, Chen M, Dai XY*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Cases*, Prashanth Panta, MDS, Reader (Associate Professor), Department of Oral Medicine and Radiology, Malla Reddy Institute of Dental Sciences, Suraram 500055, Telangana, India. maithreya.prashanth@gmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

**INDEXING/ABSTRACTING**

The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2021 Edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJCC as 1.337; IF without journal self cites: 1.301; 5-year IF: 1.742; Journal Citation Indicator: 0.33; Ranking: 119 among 169 journals in medicine, general and internal; and Quartile category: Q3. The WJCC's CiteScore for 2020 is 0.8 and Scopus CiteScore rank 2020: General Medicine is 493/793.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Lin-YuTong Wang; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

**NAME OF JOURNAL**

*World Journal of Clinical Cases*

**ISSN**

ISSN 2307-8960 (online)

**LAUNCH DATE**

April 16, 2013

**FREQUENCY**

Thrice Monthly

**EDITORS-IN-CHIEF**

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

**PUBLICATION DATE**

February 16, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report

Juan Wang, Yong-Sheng Gao, Kun Xu, Xiao-Dong Li

**ORCID number:** Juan Wang 0000-0002-0508-8895; Yong-Sheng Gao 0000-0003-0095-8836; Kun Xu 0000-0003-2692-0107; Xiao-Dong Li 0000-0002-6934-2303.

**Author contributions:** Li XD designed the research study; Wang J collected data of the study; Gao YS advised on the pathological report; and Xu K wrote the manuscript; all authors have read and approve the final manuscript.

### Informed consent statement:

Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

### CARE Checklist (2016) statement:

The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Country/Territory of origin:** China

**Specialty type:** Hematology

### Provenance and peer review:

Unsolicited manuscript; Externally peer reviewed.

**Juan Wang, Xiao-Dong Li,** Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, Shandong Province, China

**Yong-Sheng Gao,** Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, Shandong Province, China

**Kun Xu,** Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, Shandong Province, China

**Corresponding author:** Xiao-Dong Li, MD, PhD, Doctor, Professor, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Road, Jinan 250117, Shandong Province, China. [sylxd1306@163.com](mailto:sylxd1306@163.com)

## Abstract

### BACKGROUND

The prognosis of refractory extranodal natural killer/T-cell lymphoma (ENKTL) is poor. Recent data have indicated that immune checkpoint blockade with a programmed cell death protein-1 (PD-1) antibody in combination with administration of histone deacetylase inhibitors represents a potentially effective treatment strategy. Compared with PD-1 antibodies, programmed death-ligand 1 antibodies have fewer side effects. Here, we present a rare case of a patient with refractory metastatic ENKTL who achieved sustained remission of approximately 10 mo with minor adverse effects after combination therapy with atezolizumab, chidamide, and radiotherapy.

### CASE SUMMARY

A 56-year-old woman underwent resection of a tumour in her left nasal cavity and was diagnosed with ENKTL (nasal type). Medical examination revealed tumours observed in the bilateral nasal mucosa, the subcutaneous soft tissue of the inner side of the left eye, the soft tissue of the nasopharynx, the bilateral tonsils, and the left preauricular, right hilar, bilateral neck lymph nodes and bone marrow. However, tomography/computed tomography showed increased metabolism of

**Peer-review model:** Single blind**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Received:** July 30, 2021**Peer-review started:** July 30, 2021**First decision:** October 25, 2021**Revised:** November 7, 2021**Accepted:** January 6, 2022**Article in press:** January 6, 2022**Published online:** February 16, 2022**P-Reviewer:** Shekouhi R**S-Editor:** Wang LYT**L-Editor:** A**P-Editor:** Wang LYT

the bilateral nasal mucosa and subcutaneous soft tissue of the inner side of the left eye and newly increased metabolism of the left cervical lymph node after chemotherapy. Therefore, combination therapy with chidamide, atezolizumab, and radiotherapy was performed. Fortunately, the patient achieved a complete response following 10 mo of combination therapy.

**CONCLUSION**

The outcome in this case suggests that the combination of atezolizumab, chidamide, and radiotherapy is a promising regimen for treating refractory metastatic ENKTL following chemotherapy treatment failure.

**Key Words:** Long-term remission; Refractory metastatic extranodal natural killer/T-cell lymphoma; Histone deacetylase; Programmed death-ligand 1 antibody; Radiotherapy; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** extranodal natural killer/T-cell lymphoma (ENKTL) is a subtype of non-Hodgkin lymphoma with poor outcomes because ENKTL cells express high levels of P-glycoprotein that mediate tumour multidrug resistance. Furthermore, the standard treatment modality for chemotherapy-resistant ENKTL remains debated. We have experienced a patient with refractory metastatic ENKTL who was resistant to conventional DDGP chemotherapy. Following systemic therapy with atezolizumab and chidamide in combination with local radiotherapy, the patient achieved sustained remission of approximately 10 mo with minor adverse effects.

**Citation:** Wang J, Gao YS, Xu K, Li XD. Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report. *World J Clin Cases* 2022; 10(5): 1609-1616

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i5/1609.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v10.i5.1609>

**INTRODUCTION**

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a distinct subtype of mature T-cell and NK-cell lymphoma that is prevalent in regions of East Asia and South America[1-3]. ENKTL progresses rapidly and has a poor prognosis. Although options for therapy continue to evolve, their curative effects remain unsatisfactory. Because ENKTL cells express high levels of P-glycoprotein that mediate tumour multidrug resistance, conventional chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) have poor outcomes. Thus, nonanthracycline-based chemotherapy has become the main therapeutic strategy. However, in patients for whom L-asparaginase-based regimens are ineffective, progression-free survival (PFS) after relapse or first progression was only 4.1 mo[4].

Recently, several studies have reported that HDAC inhibitors (HDACis) combined with anti-death protein-1 (PD-1) immunotherapy showed encouraging efficacy, thus representing a new treatment strategy for relapsed/refractory (r/r) ENKTL[5,6]. However, the combination of death-ligand 1 (PD-L1) antibody and HDACi for r/r ENKTL has not yet been investigated. Here, we report the case of a patient with refractory metastatic ENKTL who achieved a durable response following systemic therapy with PD-L1 antibody and chidamide in combination with local radiotherapy.

**CASE PRESENTATION****Chief complaints**

A 56-year-old woman had been diagnosed with ENKTL (nasal type) for one month.

**History of present illness**

The patient underwent resection of a tumour in her left nasal cavity and was diagnosed with ENKTL (nasal type). Before being transferred to our hospital, she accepted her first cycle chemotherapy with CHOPE (cyclophosphamide 1000 mg Day 1 + vincristine 2 mg Day 1 + epirubicin 100 mg Day 1 + etoposide 100 mg Days 1-3 + prednisone acetate 100 mg Days 1-5) and developed grade IV myelosuppression.

**History of past illness**

The patient had a free previous medical history.

**Personal and family history**

Personal and family history was non-contributory.

**Physical examination**

The patient's temperature was 36.4 °C, heart rate was 102 beats/min, respiratory rate was 25 breaths/min, and blood pressure was 122/95 mmHg. The clinical examination revealed facial strut and pain.

**Laboratory examinations**

The tumour cells stained positive for CD3, CD56, TIA-1, and Ki-67 (approximately 40%) but were negative for CD20 (Figure 1). Bone marrow examination was performed. Flow cytometry revealed 0.71% NK cells with the following abnormal immunophenotypes: CD2+, CD7+, CD56+, CD94+, CD161+, CD5-, CD16-, and CD8+/-.

**Imaging examinations**

Positron emission tomography/computed tomography (PET/CT) was performed for staging, and increased <sup>18</sup>F-fluorodeoxyglucose (FDG) uptake was observed in the bilateral nasal mucosa, the subcutaneous soft tissue of the inner side of the left eye, the soft tissue of nasopharynx, the bilateral tonsils, and the left preauricular, right hilar, and bilateral neck lymph nodes. These patterns were consistent with the infiltration of malignant lymphoma (Figure 2).

---

**FINAL DIAGNOSIS**

The patient was diagnosed with ENKTL (nasal type). Disease was evaluated as Ann Arbor stage IVE A, the prognostic index for NK/T-cell lymphoma, including Epstein-Barr virus DNA load (PINK-E), was calculated as 3, and disease was classified as high risk.

---

**TREATMENT**


Radiotherapy, chidamide, and nivolumab were concurrently administered. The target volume included the partial frontal sinus, the right maxillary sinus, all ethmoid sinuses, the sphenoid sinus, the left orbit and eye contents, the left maxillary sinus, the nasopharynx, the left preauricular lymphoid drainage area, and the bilateral neck level Ib, 2, 3, 4, and 5 Lymphatic drainage areas. The radiation dose was 50 Gy/25 fractions. The patient developed transient rash on the third day after nivolumab treatment and grade 4 thrombocytopenia following the first cycle of combination therapy. Therefore, the PD-1/PD-L1 inhibitor was changed to atezolizumab for subsequent immunotherapy after her haemogram recovered.

---

**OUTCOME AND FOLLOW-UP**

After four cycles of chidamide and atezolizumab, PET/CT showed slightly higher metabolism of the nasal cavity. Treatment was continued as planned. Fortunately, PET/CT showed no obvious FDG uptake after 11 cycles of combination therapy with chidamide and atezolizumab (Figure 2). Grade 3 adverse events, including neutropenia and thrombocytopenia, were manageable and resolved during maintenance treatment.





**Figure 1** Photomicrographs of the left nasal cavity biopsy demonstrating extranodal natural killer/T-cell lymphoma. Immunohistochemical staining showed that the tissue of the left nasal cavity mass was positive for CD3, TIA-1, Ki67, and CD56 but negative for CD20.

## DISCUSSION

ENKTL is a subtype of non-Hodgkin lymphoma with poor outcome. The standard treatment modality for refractory ENKTL is still debated, especially for chemotherapy-resistant tumours[4]. Here, we present the case of a patient with refractory metastatic ENKTL who was resistant to conventional DDGP chemotherapy. Following systemic therapy with a PD-L1 inhibitor and chidamide in combination with local radiotherapy, the patient achieved sustained remission of approximately 10 mo with minor adverse effects.

Previous studies suggested that NKTL was resistant to anthracycline[7]. Thus, pegaspargase, gemcitabine, or other non-anthracycline-based chemotherapy regimens are generally used for the first-line treatment of patients with newly diagnosed refractory NKTL[8,9]. Additionally, as described in previous reports, allogeneic stem cell transplantation (allo-SCT) may be beneficial for patients with ENKTL[10,11]. However, PFS in the subset of patients who maintained remission following allo-SCT was only approximately 10.0 mo. There has been no randomized, prospective study to evaluate the safety and efficacy of allo-SCT in ENKTL[12].

Recently, radiotherapy, PD-1 inhibitors, and HDACis (alone or in combination) have shown promising efficacy in treating r/r ENKTL. Chidamide is a novel benzamide-type HDACi that can selectively block HDAC1, 2, 3, and 10[13]. Recent data demonstrated that chidamide induced growth inhibition and apoptosis in NK/T lymphoma cells[14]. A phase II clinical trial of chidamide for r/r peripheral T-cell lymphoma showed median PFS and overall survival of 2.1 and 21.4 mo, respectively [15]. In this study, 16 ENKTL patients were enrolled and showed lower response rates compared with other studies: one patient achieved a complete response (CR), and two patients achieved partial responses (PRs).

PD-1/PD-L1 inhibitors are additional new agents for the treatment of r/r ENKTL. In previous reports (Table 1), combining PD-1 antibody with chemotherapy or chidamide obtained satisfactory results, and most of the cases achieved complete response and sustained curative effects[16-21]. The anti-PD-1 antibody (sintilimab) plus chidamide regimen was evaluated in a phase 1b/II clinical trial[22], where the CR rate was 44.4% in 41 r/r-NKTCL patients. A previous study demonstrated that anti-

**Table 1 Reports regarding the application of death protein-1/death-ligand 1 inhibitors in refractory or relapsed extranodal natural killer/T-cell lymphoma**

Ref.	Number of cases	Age mean year (range)	Gender	Treatment	Stage	Response	OS or PFS
McGehee <i>et al</i> [16] 2021	1	72	1 M	Pembrolizumab plus RT	IV	CR	33 mo, alive
Du <i>et al</i> [17] 2020	3	52 (51-54)	3 M	PD-1 antibody, plus Chidamide, etoposide, and thalidomide	1 (33.3%) IV; 1 (33.3%) III; 1 (33.3%) II	2 (66.7%) CR; 1 (33.3%) PD	-
Kwong <i>et al</i> [18] 2017	7	49 (31-68)	7 M	Pembrolizumab	5 (71.4%) IV; 2 (28.6%) IE	5 (71.4%) C; 2 (28.6%) PR	-
Li <i>et al</i> [19] 2018	7	47 (17-61)	4 M; 3 F	Pembrolizumab	2 (28.6%) IV; 3 (42.9%) II; 1 (14.3%) III; 1 (14.3%) IE	2 (28.6%) CR; 2 (28.6%) PR	5 mo OS; 4.8 mo PFS
Diab <i>et al</i> [20] 2021	1	82	M	Pembrolizumab	IV	CR	21 mo, alive
Lai <i>et al</i> [21] 2017	1	37	F	Pembrolizumab	IV	CR	-
Gao <i>et al</i> [22] 2020	41	48 (20-72)	27 M; 14 F	Sintilimab plus chidamide	26 (70.3%) IV; 15 (29.7%) Non-IV	16 (44.4%) CR; 5 (13.9%) PR	-
Kim <i>et al</i> [24] 2020	21	≤ 60 16; > 60 5	13 M; 8 F	Avelumab	-	5 (23.8%) CR; 3 (14.3%) PR	-

OS: Overall survival; PFS: Progression-free survival; M: Male; F: Female; Non-IV: Non-stage IV patients; RT: Radiotherapy.


PD-L1 antibodies have better efficacy and fewer adverse effects[23]. In particular, an open-label phase 2 study demonstrated that a PD-L1 antibody as a single agent induced tumour remission in a subset of patients. CRs were observed in 24% of patients, and the overall response rate was 38%; the study was terminated because of a lower than expected response rate[24]. Five responders in this study continued to show sustained responses, and the only adverse events observed were grades 1 or 2. However, to our knowledge, there have been no case reports evaluating the effects of PD-L1 antibody for r/r-ENKTL patients who could not tolerate previous treatment with PD-1 antibody.

Recently, multiple lines of evidence have demonstrated that HDACis could enhance the therapeutic effects of PD-1 antibodies[25,26]. Epigenetic modification could regulate T cell trafficking and reactivation, thus enhancing the efficacy of the PD-1 antibody. A few case reports suggested that the combination of PD-1 antibodies and HDACis might be effective in patients with refractory ENKTL[5,6]. However, the antitumour effect of combination therapy with PD-L1 antibody and chidamide has not been demonstrated for refractory ENKTL. The patient described here was successfully treated with local radiotherapy and systemic therapy with chidamide and PD-L1 antibodies. Evaluation 10 months following the end of radiation therapy showed a sustained CR. We presume that the sustained therapeutic efficacy observed in this patient may result from synergistic effects of PD-L1 antibody, chidamide, and local radiotherapy. Studies with larger numbers of patients are needed to evaluate the efficacy and safety of this combination therapy regimen for refractory ENKTL.

## CONCLUSION

We present a rare case of a patient with refractory ENKTL who was successfully treated with a combination of radiotherapy, chidamide, and PD-L1 antibody. Additional evidence is needed to evaluate the potential activity and safety of this regimen.





**Figure 2** Imaging at diagnosis, after four cycles of chemotherapy with DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase), and 10 mo posttreatment with death-ligand 1 antibody and chidamide. A: Positron emission tomography showing hypermetabolism in the bilateral nasal mucosa, the subcutaneous soft tissue of the inner side of the left eye, the soft tissue of the nasopharynx, the bilateral tonsil, and the left preauricular, bilateral neck, and right hilar lymph nodes; B: After four cycles of DDGP chemotherapy, increased metabolism of the lesions was observed except in the right hilar lymph nodes; C: Patient achieved sustained remission for approximately 10 mo.

## ACKNOWLEDGEMENTS

We thank the patient and her family for providing signed informed consent.

## REFERENCES

- 1 Shi Y. Current status and progress of lymphoma management in China. *Int J Hematol* 2018; **107**: 405-412 [PMID: 29388166 DOI: 10.1007/s12185-018-2404-8]
- 2 Haverkos BM, Pan Z, Gru AA, Freud AG, Rabinovitch R, Xu-Welliver M, Otto B, Barrionuevo C, Baiocchi RA, Rochford R, Porcu P. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. *Curr Hematol Malig Rep* 2016; **11**: 514-527 [PMID: 27778143 DOI: 10.1007/s11899-016-0355-9]
- 3 Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S, Kim SJ, Cabrera ME, Shustov AR, Chiattonne CS, Horwitz SM, Dlouhy I, Spina M, Hitz F, Montoto S, Nagler A, Martinez V, De Souza CA, Fernandez-Alvarez R, Ballova V, Gabús R, Inghirami G, Federico M, Kim WS. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. *Lancet Haematol* 2020; **7**: e284-e294 [PMID: 32105608 DOI: 10.1016/S2352-3026(19)30283-2]
- 4 Lim SH, Hong JY, Lim ST, Hong H, Arnoud J, Zhao W, Yoon DH, Tang T, Cho J, Park S, Ko YH, Kim SJ, Suh C, Lin T, Kim WS. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. *Ann Oncol* 2017; **28**: 2199-2205 [PMID: 28911074 DOI: 10.1093/annonc/mdx316]
- 5 Xu J, Xu X, Chen J, Wang J, Jiang C, Lv C, Chen B. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.



- Medicine (Baltimore)* 2021; **100**: e24824 [PMID: 33725836 DOI: 10.1097/MD.00000000000024824]
- 6 **Yan Z**, Yao S, Liu Y, Zhang J, Li P, Wang H, Chu J, Zhao S, Yao Z. Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review. *Front Oncol* 2020; **10**: 608304 [PMID: 33363038 DOI: 10.3389/fonc.2020.608304]
  - 7 **Yamaguchi M**, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. *J Clin Oncol* 2011; **29**: 4410-4416 [PMID: 21990393 DOI: 10.1200/JCO.2011.35.6287]
  - 8 **Zhang L**, Wang Y, Li X, Li L, Wang X, Sun Z, Wu J, Fu X, Zhang X, Yu H, Wang G, Chang Y, Yan J, Zhou Z, Wu X, Nan F, Li W, Zhang M. Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study. *Int J Cancer* 2021; **148**: 1470-1477 [PMID: 33034052 DOI: 10.1002/ijc.33329]
  - 9 **Wang JH**, Wang L, Liu CC, Xia ZJ, Huang HQ, Lin TY, Jiang WQ, Lu Y. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma. *Oncotarget* 2016; **7**: 29092-29101 [PMID: 27093153 DOI: 10.18632/oncotarget.8647]
  - 10 **Tse E**, Chan TS, Koh LP, Chng WJ, Kim WS, Tang T, Lim ST, Lie AK, Kwong YL. Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. *Bone Marrow Transplant* 2014; **49**: 902-906 [PMID: 24777195 DOI: 10.1038/bmt.2014.65]
  - 11 **Ennishi D**, Maeda Y, Fujii N, Kondo E, Shinagawa K, Ikeda K, Ichimura K, Yoshino T, Tanimoto M. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. *Leuk Lymphoma* 2011; **52**: 1255-1261 [PMID: 21599584 DOI: 10.3109/10428194.2011.572322]
  - 12 **Jeong SH**, Song HN, Park JS, Yang DH, Koh Y, Yoon SS, Lee HW, Eom HS, Won JH, Kim WS, Kim SJ. Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. *Biol Blood Marrow Transplant* 2018; **24**: 2471-2478 [PMID: 30064012 DOI: 10.1016/j.bbmt.2018.07.034]
  - 13 **Ning ZQ**, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X, Lu XP. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. *Cancer Chemother Pharmacol* 2012; **69**: 901-909 [PMID: 22080169 DOI: 10.1007/s00280-011-1766-x]
  - 14 **Zhou J**, Zhang C, Sui X, Cao S, Tang F, Sun S, Wang S, Chen B. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway. *Invest New Drugs* 2018; **36**: 571-580 [PMID: 29504068 DOI: 10.1007/s10637-017-0552-y]
  - 15 **Shi Y**, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Zhou D, Ning Z, Lu X. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. *Ann Oncol* 2015; **26**: 1766-1771 [PMID: 26105599 DOI: 10.1093/annonc/mdv237]
  - 16 **McGehee E**, Patel H, Pearson C, Clements K, Jaso JM, Chen W, Callan A, Desai N, Ramakrishnan Geethakumari P. Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature. *J Med Case Rep* 2021; **15**: 221 [PMID: 33926575 DOI: 10.1186/s13256-021-02798-2]
  - 17 **Du L**, Zhang L, Li L, Li X, Yan J, Wang X, Fu X, Sun Z, Zhang X, Li Z, Wu J, Yu H, Chang Y, Zhou Z, Nan F, Wu X, Tian L, Zhang M. Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases. *Onco Targets Ther* 2020; **13**: 7189-7197 [PMID: 32801749 DOI: 10.2147/OTT.S262039]
  - 18 **Kwong YL**, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. *Blood* 2017; **129**: 2437-2442 [PMID: 28188133 DOI: 10.1182/blood-2016-12-756841]
  - 19 **Li X**, Cheng Y, Zhang M, Yan J, Li L, Fu X, Zhang X, Chang Y, Sun Z, Yu H, Zhang L, Wang X, Wu J, Li Z, Nan F, Tian L, Li W, Young KH. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. *J Hematol Oncol* 2018; **11**: 15 [PMID: 29386072 DOI: 10.1186/s13045-018-0559-7]
  - 20 **Diab R**, Kamran S, Adcock B, Choucair K, Truong QV. Extra-Nodal, Nasal, Natural Killer T-Cell Lymphoma Treated With a Checkpoint Inhibitor: A Case Report of a Sustained Complete Response. *Cureus* 2021; **13**: e14654 [PMID: 34046285 DOI: 10.7759/cureus.14654]
  - 21 **Lai J**, Xu P, Jiang X, Zhou S, Liu A. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report. *BMC Cancer* 2017; **17**: 507 [PMID: 28754096 DOI: 10.1186/s12885-017-3501-4]
  - 22 **Gao Y**, Huang H, Wang X, Bai B, Zhang L, Xiao Y, Liu X, Li W, Xu W, Feng R, Chen Y, Wu H, Li J, Wu X. Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-

- ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT). *Blood* 2020; **136**: 39-40 [DOI: [10.1182/blood-2020-134665](https://doi.org/10.1182/blood-2020-134665)]
- 23 **Feng D**, Guan Y, Liu M, He S, Zhao W, Yin B, Liang J, Li Y, Wang J. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature. *Front Immunol* 2021; **12**: 608292 [PMID: [34135884](https://pubmed.ncbi.nlm.nih.gov/34135884/) DOI: [10.3389/fimmu.2021.608292](https://doi.org/10.3389/fimmu.2021.608292)]
- 24 **Kim SJ**, Lim JQ, Laurensia Y, Cho J, Yoon SE, Lee JY, Ryu KJ, Ko YH, Koh Y, Cho D, Lim ST, Enemark MB, D'Amore F, Bjerre M, Ong CK, Kim WS. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. *Blood* 2020; **136**: 2754-2763 [PMID: [32766875](https://pubmed.ncbi.nlm.nih.gov/32766875/) DOI: [10.1182/blood.2020007247](https://doi.org/10.1182/blood.2020007247)]
- 25 **Burke B**, Eden C, Perez C, Belshoff A, Hart S, Plaza-Rojas L, Delos Reyes M, Prajapati K, Voelkel-Johnson C, Henry E, Gupta G, Guevara-Patiño J. Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction. *Front Oncol* 2020; **10**: 699 [PMID: [32500025](https://pubmed.ncbi.nlm.nih.gov/32500025/) DOI: [10.3389/fonc.2020.00699](https://doi.org/10.3389/fonc.2020.00699)]
- 26 **Chen X**, Pan X, Zhang W, Guo H, Cheng S, He Q, Yang B, Ding L. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. *Acta Pharm Sin B* 2020; **10**: 723-733 [PMID: [32528824](https://pubmed.ncbi.nlm.nih.gov/32528824/) DOI: [10.1016/j.apsb.2019.09.006](https://doi.org/10.1016/j.apsb.2019.09.006)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

